MOR

MorphoSys AG

18.99 USD
-0.01 (-0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MorphoSys AG stock is up 5.62% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 71.43% of the previous 6 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 1 PUT, 9 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 May 14:05 17 May, 2024 17.50 PUT 2244 396
15 May 18:42 19 Jul, 2024 15.00 CALL 200 714
16 May 17:17 19 Jul, 2024 12.50 CALL 73 2855
16 May 17:19 19 Jul, 2024 12.50 CALL 55 2855
16 May 17:19 19 Jul, 2024 12.50 CALL 70 2855
16 May 17:19 19 Jul, 2024 12.50 CALL 103 2855
16 May 17:19 19 Jul, 2024 12.50 CALL 38 2855
16 May 17:19 19 Jul, 2024 12.50 CALL 63 2855
16 May 17:20 19 Jul, 2024 12.50 CALL 70 2855
16 May 17:21 19 Jul, 2024 12.50 CALL 55 2855

About MorphoSys AG

MorphoSys AG engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis.